539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir
Jared Pitts(Gilead Sciences (United States)), John P. Bilello(Global Vaccines (United States)), David R. Martinez(University of North Carolina at Chapel Hill), Ralph S. Baric(University of North Carolina at Chapel Hill), Raju Subramanian(Gilead Sciences (United States)), Joy Y. Feng(Gilead Sciences (United States)), Darius Babusis(Gilead Sciences (United States)), Roy Bannister(Gilead Sciences (United States)), Tomáš Cihlář(Gilead Sciences (United States)), Mazin Abdelghany(University of California, San Francisco), Rita Humeniuk(Gilead Sciences (United States)), Venice Du Pont(Gilead Sciences (United States)), Nicholas C. Riola(Gilead Sciences (United States)), Olena Anoshchenko(Gilead Sciences (United States)), Meghan S. Vermillion(Lovelace Respiratory Research Institute), Richard K. Plemper(Georgia State University), Helen Winter(Hackensack University Medical Center), Robert M. Cox(Georgia State University), Sandhya Girish(Gilead Sciences (United States)), Joe Llewellyn(Gilead Sciences (United States)), Robert H. Hyland(Gilead Sciences (United States)), Timothy P. Sheahan(University of North Carolina at Chapel Hill), Alexandra Schäfer(University of North Carolina at Chapel Hill), Richard L. Mackman(Gilead Sciences (United States))
Cited by 3
Related Papers
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k